Literature DB >> 12668587

Interactions between leptin and the human sympathetic nervous system.

Nina Eikelis1, Markus Schlaich, Anuradha Aggarwal, David Kaye, Murray Esler.   

Abstract

Results from animal experimentation suggest a 2-way interaction between leptin and the sympathetic nervous system, with leptin causing sympathetic activation and conversely, with the sympathetic system exercising regulatory feedback inhibition over leptin release. We have now tested this hypothesis in humans. In the absence of results from leptin infusions, to test for sympathetic stimulation of leptin release, we sought a quantitative naturalistic linkage of sympathetic activity with leptin plasma concentration across a broad range of leptin values in men of widely differing adiposity. Renal norepinephrine spillover was correlated with plasma leptin (r=0.628, P<0.01), but other measures of sympathoadrenal function did not. To test for sympathetic and adrenomedullary inhibition of leptin release, we studied clinical models of high sympathetic tone, heart failure, and essential hypertension, in which lowered plasma leptin levels might have been expected but were not found; a model of low sympathetic activity, pure autonomic failure, in which plasma leptin level was normal (6.1+/-1.2 vs 12.8+/-3.1 ng/mL in healthy subjects); and a clinical model of reduced epinephrine secretion, healthy aging, in which plasma leptin level again was normal (5.7+/-1.1 ng/mL vs 4.0+/-0.9 ng/mL in men >60 years and <35 years, respectively). Paradoxically, leptin concentration was elevated in heart failure, caused entirely by reduced renal clearance of leptin release, 142.0+/-30.5 mL/min, compared with 56.9+/-18.9 mL/min (P<0.05). These results provide some support for the view that leptin stimulates the sympathetic nervous system, at least for renal sympathetic outflow, but do not confirm the concept of regulatory feedback inhibition of leptin release by the sympathetic nervous system.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12668587     DOI: 10.1161/01.HYP.0000066289.17754.49

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  62 in total

Review 1.  Sympathetic nervous system in obesity-related hypertension: mechanisms and clinical implications.

Authors:  Graziela Z Kalil; William G Haynes
Journal:  Hypertens Res       Date:  2011-11-03       Impact factor: 3.872

Review 2.  Selective leptin resistance revisited.

Authors:  Allyn L Mark
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2013-07-24       Impact factor: 3.619

Review 3.  Mediators of sympathetic activation in metabolic syndrome obesity.

Authors:  Nora E Straznicky; Nina Eikelis; Elisabeth A Lambert; Murray D Esler
Journal:  Curr Hypertens Rep       Date:  2008-12       Impact factor: 5.369

Review 4.  Dietary patterns, supplement use, and the risk of benign prostatic hyperplasia.

Authors:  Kenneth S Poon; Kevin T McVary
Journal:  Curr Urol Rep       Date:  2009-07       Impact factor: 3.092

Review 5.  New approaches to quantifying sympathetic nerve activity.

Authors:  Sandra L Burke; Elisabeth Lambert; Geoffrey A Head
Journal:  Curr Hypertens Rep       Date:  2011-06       Impact factor: 5.369

6.  Effect of intestinal ischemia-reperfusion injury on protein levels of leptin and orexin-A in peripheral blood and central secretory tissues.

Authors:  Ji Lin; Guang-Tao Yan; Xiu-Hua Hao; Lu-Huan Wang; Kai Zhang; Hui Xue
Journal:  World J Gastroenterol       Date:  2005-02-21       Impact factor: 5.742

Review 7.  Neural Control of Non-vasomotor Organs in Hypertension.

Authors:  Chansol Hurr; Colin N Young
Journal:  Curr Hypertens Rep       Date:  2016-04       Impact factor: 5.369

8.  Effect of intestinal ischemia/reperfusion injury on leptin and orexin-A levels.

Authors:  Ji Lin; Guangtao Yan; Xiaoning Gao; Jie Liao; Xiuhua Hao; Kai Zhang
Journal:  Front Med China       Date:  2007-02

Review 9.  Leptin: sympathetic and cardiovascular effects.

Authors:  Robert J Richards; Anthony Blalock; Jie Liao; Efrain Reisin
Journal:  Curr Cardiol Rep       Date:  2003-11       Impact factor: 2.931

10.  The role of novel biomarkers of cardiovascular disease in chronic kidney disease: focus on adiponectin and leptin.

Authors:  Omar M Kaisar; David W Johnson; Judith B Prins; Nicole Isbel
Journal:  Curr Cardiol Rev       Date:  2008-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.